Movement disorders : official journal of the Movement Disorder Society最新文献

{"title":"Immersive Virtual Reality as a Probe of Context-Dependent Gait Control: Reply to Peh et al.","authors":"Marialuisa Gandolfi, Chiara Bonetto, Corrado Perin, Angela Sandri, Giulia Bonardi, Ilaria Antonella Di Vico, Laura Avanzino, Elisa Pelosin, Mauro Crestani, Christian Geroin, Denis Vidale, Marco Pirini, Mirta Fiorio, Michele Tinazzi, Francesca Salaorni","doi":"10.1002/mds.70582","DOIUrl":"https://doi.org/10.1002/mds.70582","url":null,"abstract":"","PeriodicalId":520713,"journal":{"name":"Movement disorders : official journal of the Movement Disorder Society","volume":" ","pages":""},"PeriodicalIF":7.6,"publicationDate":"2026-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149291894","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"High-Intensity Focused Ultrasound of Bilateral Pallidothalamic Tracts for Parkinson's Disease: Are We Ready?","authors":"Drew S Kern, Alfonso Fasano","doi":"10.1002/mds.70577","DOIUrl":"https://doi.org/10.1002/mds.70577","url":null,"abstract":"","PeriodicalId":520713,"journal":{"name":"Movement disorders : official journal of the Movement Disorder Society","volume":" ","pages":""},"PeriodicalIF":7.6,"publicationDate":"2026-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149291852","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mortality in People with Action Tremor: Findings from Three Population-Based Cohort Studies.","authors":"Katrine Lawaetz Kristensen, Jacob Krabbe Pedersen, Gregor Kuhlenbäumer, Dorte Ejg Jarbøl, Kaare Christensen, Günther Deuschl","doi":"10.1002/mds.70581","DOIUrl":"https://doi.org/10.1002/mds.70581","url":null,"abstract":"<p><strong>Background: </strong>Action tremor is common in adults and increases with age. Although essential tremor (ET) is a major subgroup, action tremor comprises heterogeneous phenotypes, and its prognostic implications remain uncertain.</p><p><strong>Objectives: </strong>Our aim was to examine the association between action tremor and all-cause mortality using complementary population-based cohorts.</p><p><strong>Methods: </strong>We triangulated data from three Danish cohorts: a nationwide register-based cohort of 3487 individuals with outpatient hospital-diagnosed ET, each matched to 10 controls; the Longitudinal Study of Aging Danish Twins (LSADT), including spiral-based tremor assessment on 2029 individuals and a neurologist-examined subgroup; and the Danish Symptom Cohort, including 2472 individuals with self-reported tremor, each matched to four controls. Mortality follow-up was obtained through nationwide registers. Cox regression models were applied with age as the time variable.</p><p><strong>Results: </strong>In the outpatient cohort, hospital-diagnosed ET was associated with increased mortality (hazard ratio [HR], 1.37, 95% confidence interval, 1.27-1.46). In LSADT, subjects with high Archimedes scores indicating symptomatic action tremor (scores 5-7 vs. 0-2) yielded HR, 1.67 (1.42-1.97). Additionally, higher spiral scores were associated with progressively lower survival. In the Danish Symptom Cohort, even self-reported tremor was associated with increased mortality (HR, 1.56, 1.38-1.75), robust to adjustment for alcohol use.</p><p><strong>Conclusions: </strong>In three population-based cohorts, action tremor was consistently associated with increased mortality. We showed that our clinically diagnosed ET-cohort, a cohort with spiral score validated action tremor, and a cohort with self-diagnosed symptomatic action tremor, all showed increased mortality. Action tremor may represent a marker of underlying health vulnerability rather than a benign motor sign. © 2026 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.</p>","PeriodicalId":520713,"journal":{"name":"Movement disorders : official journal of the Movement Disorder Society","volume":" ","pages":""},"PeriodicalIF":7.6,"publicationDate":"2026-10-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149281006","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Glymphatic Dysfunction Drives High-Urea-Induced Neurodegeneration in Parkinson's Disease.","authors":"Shengyao Zhang, Jiajie Leng, Guoran Wan, Qiongfang Wang, Meng Zhang, Xiaoyu Wang, Dilong Chen, Boyue Huang, Jianhua Ran","doi":"10.1002/mds.70565","DOIUrl":"https://doi.org/10.1002/mds.70565","url":null,"abstract":"<p><strong>Background: </strong>Disruption of brain urea homeostasis has been implicated in neurodegenerative disorders, yet its molecular mechanisms remain elusive. This study aimed to investigate how urea metabolic disturbance drives neurodegeneration through astrocytic polarity impairment and to identify potential therapeutic targets.</p><p><strong>Methods: </strong>A high-urea mouse model was generated by urea transporter B (UT-B) knockout. Pharmacological inhibition and genetic intervention were applied to examine dipeptidyl peptidase-like protein 6 (DPP6), protein kinase C eta (PKCη), and aquaporin-4 (AQP4) expression and localization in astrocytes. Glymphatic clearance, α-synuclein (α-syn) pathology propagation, and dopaminergic neurodegeneration were evaluated.</p><p><strong>Results: </strong>Urea upregulated astrocytic DPP6, activated PKCη signaling, and induced AQP4 endocytosis with loss of membrane polarity, leading to impaired glymphatic clearance, accelerated α-syn spread, and dopaminergic neuronal degeneration. Mechanistically, the DPP6-PKCη axis directly regulated AQP4 membrane localization; inhibiting this pathway pharmacologically or genetically rescued all pathological phenotypes.</p><p><strong>Conclusions: </strong>This study reveals that urea metabolic disruption promotes neurodegenerative progression via the DPP6-PKCη-AQP4 pathway by compromising astrocytic polarity, offering new therapeutic targets for Parkinson's disease. © 2026 International Parkinson and Movement Disorder Society.</p>","PeriodicalId":520713,"journal":{"name":"Movement disorders : official journal of the Movement Disorder Society","volume":" ","pages":""},"PeriodicalIF":7.6,"publicationDate":"2026-10-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149281023","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Focused Ultrasound for Essential Tremor in Denmark: Results After 1 Year of Follow-Up.","authors":"Victor Hvingelby, Pernille Kjeldsen, Bo Bergholt, Gaston Schechtmann, Erik Hvid Danielsen, Mette Møller, Erik Lisbjerg Johnsen, Skirmante Mardosiene, Torben Ellegaard Lund, Dora Grauballe, Michael Geneser, Tina Vincens Sørensen, Lisa Østergaard Bak, Martin Andreasen, Hamed Zaer, Anne Sofie Møller Andersen, Lone Andersen, Kaare Meier, Niels Juul, Alp Tankisi, Bo Jespersen, Mads Rasmussen, Winnie Bechmann Eriksen, Birgitte Barrutia, Mette Kromann, Ida Baandrup, Jette Bjørn, Rie Stjernholm, Charlotte Bræmer-Madsen, Signe Mygdal Jørgensen, Dan Bang, Nicola Pavese, Jens Christian Hedemann Sørensen, Andreas Nørgaard Glud","doi":"10.1002/mds.70587","DOIUrl":"https://doi.org/10.1002/mds.70587","url":null,"abstract":"<p><strong>Background: </strong>Essential tremor (ET) is the most common hyperkinetic movement disorder. Magnetic resonance-guided focused ultrasound thalamotomy (MRgFUSTh) has become an established therapy in drug-refractory tremor as one treatment option. Here, we present the results of a large cohort of MRgFUSTh-treated ET patients followed-up 1 year post-ablation.</p><p><strong>Objective: </strong>The primary endpoint durability of tremor reduction at 12 months at this timepoint.</p><p><strong>Methods: </strong>This was a single-hospital cohort study. Prior to, and 12 months after, treatment, patients were rated according to the Fahn-Tolosa-Marin (FTM) scale, Quality of Life in Essential Tremor (QUEST) scale, Patient Global Assessment of Change (PGIC), as well as general health, well-being, and factors relating to social and everyday activities. Finally, side effects and adverse event data were collected at 12 months.</p><p><strong>Results: </strong>The current cohort comprised 111 patients. Patients showed good response to MRgFUSTh with a mean decrease of 29.5 points in the total FTM-score from pretreatment (95% CI: 26.3; 32.8, P < 0.0001) corresponding to 62.4% (95% CI: 56.4%; 68.5%). This meant a reduction in the FTM-score of 13.8 points (± 5.2 points, 95% CI: 12.79; 14.73, P < 0.00001) or 85.2% (±24.2%, 95% CI: 80.70%; 89.78%) in the treated limb. For QUEST, symptoms improved by 20.9 points (95% CI: 12.1; 29.6, P < 0.0001) corresponding to a relative improvement of 54% (95% CI: 33.2%; 75.5%).</p><p><strong>Conclusion: </strong>Results showed clear and persistent tremor improvements as assessed by both clinicians and patients. © 2026 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.</p>","PeriodicalId":520713,"journal":{"name":"Movement disorders : official journal of the Movement Disorder Society","volume":" ","pages":""},"PeriodicalIF":7.6,"publicationDate":"2026-10-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149281018","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Latent Class Trajectory Modeling Identifies Cerebrospinal Fluid Protein Signatures Associated with Motor Progression in Parkinson's Disease: Evidence from the Parkinson's Progression Markers Initiative Cohort.","authors":"Shunyao Qi, Yao Wu, Ming Chao, Lijia Xu, Peigen Xiao","doi":"10.1002/mds.70589","DOIUrl":"https://doi.org/10.1002/mds.70589","url":null,"abstract":"<p><strong>Background: </strong>Motor progression in Parkinson's disease (PD) is highly heterogeneous, limiting prognosis and the efficiency of clinical trials that require accurate risk stratification. Traditional modeling approaches assume a single average trajectory and fail to capture meaningful divergence, whereas the biological determinants of trajectory-defined subtypes remain unclear. Multivariate proteomic biomarkers may improve early identification of rapid progressors.</p><p><strong>Objectives: </strong>We aimed to (1) delineate distinct motor progression subtypes in early PD using longitudinal Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) III scores and (2) identify cerebrospinal fluid (CSF) proteomic signatures that discriminate rapid from slow progressors.</p><p><strong>Methods: </strong>We analyzed 5-year longitudinal data from 396 Parkinson's Progression Markers Initiative (PPMI) participants with early PD. Motor progression trajectories were derived using latent class trajectory modeling (LCTM) of repeated MDS-UPDRS III scores. CSF proteomics from 78 Olink samples were used for biomarker discovery, with least absolute shrinkage and selection operator (LASSO)-based feature selection followed by multivariable logistic regression. Validation was performed in 184 SOMAscan-profiled samples.</p><p><strong>Results: </strong>LCTM identified distinct motor progression subtypes in early PD. Differential CSF protein expression across these trajectories highlighted candidate markers of rapid decline. A seven-protein signature (CCL27, CXCL9, NEFL, SERPINE1, GH1, TYMP, KLK1) exhibited good discriminative performance for distinguishing rapid from slow progressors (area under the curve [AUC] = 0.908). In an independent cohort, the combined model showed consistent directional effects and achieved the highest accuracy (AUC = 0.796).</p><p><strong>Conclusions: </strong>Integrating trajectory modeling with CSF proteomics identified a concise seven-protein signature associated with early PD progression, which showed reproducible patterns across two PPMI cohorts. This approach may support improved risk stratification in PD. © 2026 International Parkinson and Movement Disorder Society.</p>","PeriodicalId":520713,"journal":{"name":"Movement disorders : official journal of the Movement Disorder Society","volume":" ","pages":""},"PeriodicalIF":7.6,"publicationDate":"2026-10-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149248128","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Remote Versus In-Person Follow-up Programming After Subthalamic Deep Brain Stimulation for Parkinson's Disease: A Multicenter Randomized Noninferiority Trial.","authors":"Juhi Shaik, Weidong Zhang, Verena Zentsch, Carsten Buhmann, Ute Hidding, Thomas M Kinfe, Martin Regensburger, Jost-Julian Rumpf, Alfons Schnitzler, Jing Dong, Maximilian Scherer, Elisabeth Kaufmann, Johannes Levin, Alexander Crispin, Günter Höglinger, Jan H Mehrkens, Thomas Koeglsperger","doi":"10.1002/mds.70575","DOIUrl":"https://doi.org/10.1002/mds.70575","url":null,"abstract":"<p><strong>Background: </strong>Remote programming of deep brain stimulation may improve access to specialized postoperative care for people with Parkinson's disease, but prospective randomized evidence remains limited.</p><p><strong>Objective: </strong>We aimed to determine whether remote follow-up programming after standardized inpatient initiation is noninferior to conventional in-person follow-up programming for motor outcomes during the early postoperative period.</p><p><strong>Methods: </strong>In this prospective, randomized, open-label, multicenter noninferiority trial, adults with idiopathic Parkinson's disease who recently underwent bilateral subthalamic nucleus deep brain stimulation implantation at six German centers were randomly assigned 1:1 to conventional in-person follow-up programming or remote follow-up programming through a secure telemedicine platform during the first 90 days after surgery. All participants underwent initial in-person postoperative programming before randomization. The primary outcome was the Movement Disorder Society-Unified Parkinson's Disease Rating Scale Part III score at 90 days in the medication on and stimulation ON state. The prespecified noninferiority margin was 5 points.</p><p><strong>Results: </strong>Fifty-two participants were randomly assigned. The per-protocol population included 26 participants in the conventional care group and 22 in the remote programming group. The between-group median difference of the primary endpoint was -2.5 points (95% confidence interval, -9.0 to 2.0), meeting the prespecified noninferiority criterion. Secondary clinical outcomes and patient-reported outcomes were broadly comparable between groups. Serious adverse events occurred at similar frequencies in both groups, and no deaths occurred.</p><p><strong>Conclusions: </strong>Remote follow-up programming after standardized inpatient initiation achieved motor outcomes noninferior to conventional in-person follow-up during the first 3 months, with no clear short-term safety signal. © 2026 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.</p>","PeriodicalId":520713,"journal":{"name":"Movement disorders : official journal of the Movement Disorder Society","volume":" ","pages":""},"PeriodicalIF":7.6,"publicationDate":"2026-10-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149248131","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"SLC20A2 Intragenic Structural Variants as a Cause of Primary Brain Calcification.","authors":"Wen-Hao Xiao, Dan-Dan Zuo, Ze-Hong Zheng, Ya-Fang Chen, Xin-Xin Guo, Min-Kun Fang, Xiang-Ping Yao, Hui-Zhen Su, Xue-Wen Cheng, Ning Wang, Miao Zhao, Wan-Jin Chen, Ling Fang, Jin-Lan Li, Yi-Heng Zeng","doi":"10.1002/mds.70576","DOIUrl":"https://doi.org/10.1002/mds.70576","url":null,"abstract":"<p><strong>Background: </strong>Intragenic structural variants of SLC20A2 remain poorly characterized in primary brain calcification (PBC).</p><p><strong>Objectives: </strong>The aim was to identify and characterize intragenic SLC20A2 structural variants in PBC.</p><p><strong>Methods: </strong>One familial PBC pedigree and two sporadic patients underwent whole-genome sequencing and copy-number analysis, followed by polymerase chain reaction (PCR) and Sanger validation. Long-read sequencing (LRS) resolved complex architecture. Transcript and protein effects were assessed by reverse transcription (RT)-PCR, RT-quantitative PCR, and western blotting.</p><p><strong>Results: </strong>We identified three intragenic SLC20A2 structural variants: exon 2-3 and exon 5 tandem duplications in F1 and F3, respectively, and a complex exon 2-3 inverted insertion in F2. F1 and F3 showed aberrant, frameshift-generating transcripts, and F3 showed reduced SLC20A2 mRNA and protein. Accordingly, the F1 and F3 variants were classified as pathogenic, whereas the F2 variant remained of uncertain significance.</p><p><strong>Conclusions: </strong>Our study expands the spectrum of intragenic SLC20A2 structural variation in PBC and highlights the value of copy number variation analysis and LRS in genetically unresolved individuals. © 2026 International Parkinson and Movement Disorder Society.</p>","PeriodicalId":520713,"journal":{"name":"Movement disorders : official journal of the Movement Disorder Society","volume":" ","pages":""},"PeriodicalIF":7.6,"publicationDate":"2026-10-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149248143","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Automated Magnetic Resonance Volumetry to Measure Multiple System Atrophy Disease Progression in Clinical Trials.","authors":"Andrea Quattrone, Ida Wilkens, Zeyu Zhu, Irfan A Qureshi, Nicolai Franzmeier, Günter U Höglinger","doi":"10.1002/mds.70585","DOIUrl":"https://doi.org/10.1002/mds.70585","url":null,"abstract":"<p><strong>Background: </strong>Recent studies have reported longitudinal brain atrophy in multiple system atrophy (MSA) in relatively small patient cohorts.</p><p><strong>Objective: </strong>To compare longitudinal regional brain volume and clinical changes as endpoint measures for MSA clinical trials.</p><p><strong>Methods: </strong>MSA patients with 1-year longitudinal brain magnetic resonance imaging (MRI) were selected from the placebo arm of the M-STAR Study (NCT03952806) and stratified into MSA-cerebellar (MSA-C) and MSA-parkinsonism (MSA-P) subtypes. A multisite healthy control (HC) cohort from international datasets was included for comparison. Baseline and longitudinal atrophy were assessed through automated MRI volumetry. Standardized longitudinal effect size values with 95% confidence intervals (CIs) and sample sizes required to detect treatment effect were estimated for 42 individual regional brain volumes, four combined volumetric indexes, nine clinical scales, and serum neurofilament light chain.</p><p><strong>Results: </strong>The final study cohort included 129 MSA patients (76 MSA-C, 53 MSA-P) and 184 HC. The most atrophic structures at baseline were infratentorial regions in MSA-C and putamen in MSA-P. In both subtypes, infratentorial structures showed the largest longitudinal volume loss compared with HC. The annualized change of a cerebellum-pons-putamen volumetric index was the most powerful progression biomarker in MSA patients (effect size: -1.81 [95% CI: -2.14, -1.55]) and in both subtypes (MSA-C: -2.04 [95% CI: -2.58, -1.68], MSA-P: -1.55 [95% CI: -2.08, -1.22]), requiring the lowest sample size per arm (MSA, N = 55 to detect 30% treatment effect), and outperforming clinical measures (-59.6% patients required per arm).</p><p><strong>Conclusion: </strong>These findings support longitudinal MRI-derived regional atrophy rates as sensitive imaging endpoints to assess treatment efficacy in MSA clinical trials. © 2026 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.</p>","PeriodicalId":520713,"journal":{"name":"Movement disorders : official journal of the Movement Disorder Society","volume":" ","pages":""},"PeriodicalIF":7.6,"publicationDate":"2026-10-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149225718","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Power of Two: Combined MSH3/HTT Silencing in Huntington's Disease.","authors":"Beril Ay, Darius Ebrahimi-Fakhari","doi":"10.1002/mds.70578","DOIUrl":"https://doi.org/10.1002/mds.70578","url":null,"abstract":"","PeriodicalId":520713,"journal":{"name":"Movement disorders : official journal of the Movement Disorder Society","volume":" ","pages":""},"PeriodicalIF":7.6,"publicationDate":"2026-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149198839","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}